A Multi-center, Randomized, Double Blind, Placebo-controlled, 'add-on' Study to Investigate the Efficacy and Safety of 24 Weeks Intravenous Treatment With QAX576 in Patients (greater than or equal to 18-75 Years) With Persistent Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting beta2-agonists.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Dectrekumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jun 2012 Additional location (Czech Republic) added as reported by European Clinical Trials Database record.
- 03 May 2012 Actual patient number 259 added as reported by ClinicalTrials.gov.
- 03 May 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.